Amgen, UCB Seek Marketing Approval For Osteroposis Drug In Japan

Thousand Oaks-based Amgen and drug mamker UCB said on Monday that the two have submitted an application for marketing approval of romosozumab, for the treatment of osteoporosis, in Japan. The two, who are in a deal to co-develop the compound worldwide, said the effort in Japan is being led by Amgen Astellas BioPharma (AABP) K.K., a joint venture between Amgen and Astellas Pharma Inc. Amgen is in the midst of similar regulatory filings in the U.S., to use the new drug for treatment of osteoporosis in postmenopausal women at increased risk of fractures.